Brief: Athersys Reports Interim Analysis Results Of Masters-2 Clinical Study With Multistem In Ischemic Stroke, Signs Memorandum Of Understanding (MoU) For Global Ards License With Healios

Athersys

10/10/2023 13:59

Oct 10 (Reuters) - Athersys Inc  ATHX.O :
    * ATHERSYS REPORTS INTERIM ANALYSIS RESULTS OF MASTERS-2
CLINICAL
STUDY WITH MULTISTEM IN ISCHEMIC STROKE, SIGNS MEMORANDUM OF
UNDERSTANDING (MOU) FOR GLOBAL ARDS LICENSE WITH HEALIOS
    * ATHERSYS INC - MOU INCLUDES $1.5M TO $4.5M NEAR TERM
PAYMENTS
PLUS UP TO $150M IN MILESTONES
    * ATHERSYS - CONCLUDED THAT CURRENT SAMPLE SIZE OF 300
PATIENTS IS
INSUFFICIENTLY POWERED TO ACHIEVE PRIMARY ENDPOINT OF MRS SHIFT
ANALYSIS AT DAY 365
    * ATHERSYS INC - THERE WERE NO SAFETY ISSUES IDENTIFIED
    * ATHERSYS INC - ATHERSYS INTENDS TO CONDUCT ADDITIONAL DATA
ANALYSIS WITH INDEPENDENT STATISTICIANS
    * ATHERSYS INC - COMPANY PLANS TO PAUSE ENROLLMENT OF NEW
PATIENTS
WHILE THIS ANALYSIS IS BEING CONDUCTED
    * ATHERSYS INC- EXPECTS TO HAVE TO FILE FOR PROTECTION UNDER
BANKRUPTCY LAWS TO ALLOW COMPANY TO CONDUCT AN ORDERLY WIND DOWN
OF OPERATIONS
    * ATHERSYS INC - ENTERED INTO MEMORANDUM OF UNDERSTANDING
GRANTING
HEALIOS K.K. GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE
MULTISTEM
    * ATHERSYS - ENTERED INTO MOU GRANTING HEALIOS K.K. GLOBAL
RIGHTS
TO DEVELOP & COMMERCIALIZE MULTISTEM FOR TREATMENT OF ACUTE
RESPIRATORY DISTRESS SYNDROME
    * ATHERSYS INC - ALSO EXPECTS TO RECEIVE REVENUE FROM SALE
OF
EXISTING CLINICAL DOSES OF MULTISTEM
    * ATHERSYS INC- IN INTERIM, COMPANY IS STREAMLINING ITS
OPERATIONS
TO PRESERVE ITS CAPITAL AND CASH RESOURCES
    * ATHERSYS INC - INTENDS TO CONTINUE EXPLORING AVAILABLE
STRATEGIC
OPTIONS

Source text for Eikon:  ID:nBw2J9t37a 
Further company coverage:  ATHX.O 

 ((Reuters.Briefs@thomsonreuters.com))